Anti-PD-1, IMiD combo immunotherapy active in heavily pretreated myelomaDecember 12, 2015Lymphoma & Plasma Cell Disorders
VIDEO: Top-line results from Tourmaline in multiple myeloma, plus ongoing trials and treatment selectionDecember 7, 2015Lymphoma & Plasma Cell Disorders
ASH: Daratumumab and len/dex produce high response rates in refractory myelomaDecember 7, 2015Lymphoma & Plasma Cell Disorders
ASH: First-line ibrutinib beats standard chemo for CLL/SLL in older patientsDecember 7, 2015Lymphoma & Plasma Cell Disorders
VIDEO: Targeted agent, len/dex combo perform ‘impressively’ in advanced multiple myelomaDecember 7, 2015Lymphoma & Plasma Cell Disorders
ASH: Gene therapy restores immune function to older children with SCID-X1December 5, 2015Lymphoma & Plasma Cell DisordersRare Diseases
ASH: Carfilzomib doubles progression free survival in head-to-head trial with bortezomibDecember 5, 2015Lymphoma & Plasma Cell Disorders
Expert panel issues guidelines for treatment of hematologic cancers in pregnancyDecember 1, 2015Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell Disorders
Study: Pediatric cancer patients have high rate of germline mutations in predisposition genesNovember 18, 2015PediatricsLymphoma & Plasma Cell DisordersPreventive Care
Multiple myeloma advances in diagnosis, staging, therapy extend survivalNovember 11, 2015Lymphoma & Plasma Cell Disorders
